Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis

被引：89

作者：

Williams-Herman D. ^{[1
]}

Round E. ^{[1
]}

Swern A.S. ^{[1
]}

Musser B. ^{[1
]}

Davies M.J. ^{[1
]}

Stein P.P. ^{[1
]}

Kaufman K.D. ^{[1
]}

Amatruda J.M. ^{[1
]}

机构：

[1] Merck Research Laboratories, Rahway, NJ

来源：

BMC Endocrine Disorders | / 8卷 / 1期

关键词：

Metformin; Hypoglycemia; Exenatide; Sitagliptin; Vildagliptin;

D O I：

10.1186/1472-6823-8-14

中图分类号：

学科分类号：

摘要：

Background: Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral antihyperglycemic agents (AHAs) for the treatment of patients with type 2 diabetes. Type 2 diabetes is a life-long disease requiring chronic treatment and management. Therefore, robust assessment of the long-term safety and tolerability of newer therapeutic agents is of importance. The purpose of this analysis was to assess the safety and tolerability of sitagliptin by pooling 12 large, double-blind, Phase IIb and III studies up to 2 years in duration. Methods: This analysis included 6139 patients with type 2 diabetes receiving either sitagliptin 100 mg/day (N = 3415) or a comparator agent (placebo or an active comparator) (N = 2724; non-exposed group). The 12 studies from which this pooled population was drawn represent the double-blind, randomized, Phase IIB and III studies that included patients treated with the clinical dose of sitagliptin (100 mg/day) for at least 18 weeks up to 2 years and that were available in a single safety database as of November 2007. These 12 studies assessed sitagliptin as monotherapy, initial combination therapy with metformin, or add-on combination therapy with other oral AHAs (metformin, pioglitazone, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone). Patients in the non-exposed group were taking placebo, pioglitazone, metformin, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone. This safety analysis used patient-level data from each study to evaluate clinical and laboratory adverse experiences. Results: For clinical adverse experiences, the incidence rates of adverse experiences overall, serious adverse experiences, and discontinuations due to adverse experiences were similar in the sitagliptin and non-exposed groups. The incidence rates of specific adverse experiences were also generally similar in the two groups, with the exception of an increased incidence rate of hypoglycemia observed in the non-exposed group. The incidence rates of drug-related adverse experiences overall and discontinuations due to drug-related adverse experiences were higher in the non-exposed group, primarily due to the increased incidence rate of hypoglycemia in this group. For cardiac- and ischemia-related adverse experiences (including serious events), there were no meaningful between-group differences. No meaningful differences between groups in laboratory adverse experiences, either summary measures or specific adverse experiences, were observed. Conclusion: In patients with type 2 diabetes, sitagliptin 100 mg/day was well tolerated in clinical trials up to 2 years in duration. © 2008 Williams-Herman et al; licensee BioMed Central Ltd.

引用

共 40 条

[1]

Herman G.A., Stein P.P., Thornberry N.A., Wagner J.A., Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin, Clin Pharmacol Ther, 81, pp. 761-767, (2007)

[2]

Herman G.A., Stevens C., Van Dyck K., Bergman A., Yi B., De Smet M., Et al., Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects, Clin Pharm Therap, 78, pp. 675-688, (2005)

[3]

Drucker D.J., Nauck M.A., GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes, Lancet, 368, pp. 1696-1705, (2006)

[4]

Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E., Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes, Diabetes Care, 29, pp. 2632-2637, (2006)

[5]

Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus, Diabetologia, 49, pp. 2564-2571, (2006)

[6]

Scott R., Wu M., Sanchez M., Stein P.P., Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes, Int J Clin Pract, 61, pp. 171-180, (2007)

[7]

Nonaka K., Kakikawa T., Sato A., Okuyama K., Fujimoto G., Kato N., Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes, Diabetes Res Clin Pract, 79, pp. 291-298, (2008)

[8]

Hanefeld M., Herman G.A., Wu M., Mickel C., Sanchez M., Stein P.P., Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes, Curr Med Res Opin, 23, pp. 1329-1339, (2007)

[9]

Charbonnel B., Karasik A., Liu J., Wu M., Meininger G., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone, Diabetes Care, 29, pp. 2638-2643, (2006)

[10]

Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin, Diabetes Obes Metab, 9, pp. 733-745, (2007)

← 1 2 3 4 →